CLINICAL_TRIALS
trial_result
· 2021-09-22
Clinical Trial Update: A Study to Evaluate the Efficacy and Safety of SEP-363856 in Acutely Psychotic Adults With Schizophrenia [Phase 2]
Summary
Phase 2 study evaluating the efficacy and safety of SEP-363856 in acutely psychotic adults with schizophrenia has completed and posted results.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc. | Conditions: Schizophrenia | Phase 2 | Status: COMPLETED | Results posted: 2021-09-22